Core Insights - Interest in "China Travel" is increasing significantly due to streamlined visa, transportation, payment, and departure tax refund policies, with foreign inbound tourists reaching 7,367,400 in Q1 2025, marking a 39.2% year-on-year increase [1] Company Developments - Alibaba Group's Amap launched China's first multilingual map on July 9, 2025, expanding from existing Chinese and English versions to support 14 additional languages including Spanish, Portuguese, French, and more [2] - Amap previously introduced an English-language map for overseas users, enhancing the travel experience in China [3] - The multilingual version of Amap features a fully localized interface and geographic information, aiding foreign visitors in navigating China [4] Service Enhancements - The multilingual Amap integrates core functions such as driving, walking, cycling, and public transport navigation, providing services comparable to local users [5] - Amap includes an English-language ride-hailing function, allowing foreign visitors to book vehicles easily while accessing key information like pick-up locations and fare estimates [5] - Amap aims to continue enhancing its multilingual services to cover more languages and usage scenarios for overseas users [6]

7月4日晚，2025"上海之夏"国际消费季(以下简称"上海之夏")正式启动。为大力提振"入境消费和外来消 费"，2025"上海之夏"将聚焦"让全球旅客好来、好玩、好购"，通过"活动+产品+服务+政策"，充分展现 上海的夏日活力和魅力。在活动策划宣传、消费环境打造等方面突出国际化。根据日韩、东南亚、欧美 等不同地区游客特点，差异化打造各项活动和特色产品，提升上海国际消费中心城市全球吸引力。 "上海之夏"推出十大标杆活动。李秋莹摄 "上海之夏"体验官。李秋莹摄 久事集团上海公共交通卡集团董事长周耀东表示："今年'上海之夏'打造升级版Shanghai Pass城市定制 卡，融合'交通、旅游、购物、餐饮'多元优惠于一体。Shanghai Pass城市定制卡无需实名认证就可激 活、即买即用，在提供基础交通功能服务外，整合浦江游览、豫园、双层巴士等游览产品，叠加新天 地、淮海中路、徐家汇等商圈消费优惠。升级推出多日通票，联动更多景点、更多优惠、带动更多消 费。" 据悉，"上海之夏"国际消费季是以促进暑期入境消费为主的城市活动品牌，首届"上海之夏"活动期间境 外旅客人数同比增长42.2%，外卡消费总额同比增长68.2%。今 ...

Medicines for the Brain Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB) LS Honig1 , SN Gomperts2 , JP Taylor3 , ND Prins4 , A Gardner5 , K Blackburn5 , JJ Alam5 , JE Galvin6 1. Columbia University Irving Medical Center – New York, NY (United States); 2. Massachusetts General Hospital – Charlestown, MA (United States); 3. Newcastle University - Newcastle Upon Tyne (United Kingdom); 4. Brain Research Center, Amsterdam (Netherlands); 5. Ce ...

Shares of MIND Technology, Inc. (MIND) have declined 10.6% since the company reported its fiscal first quarter earnings for the period ended April 30, 2025, significantly underperforming the S&P 500 index, which dipped just 0.5% over the same timeframe. Over the past month, the stock has retreated 4.9% compared to the broader market’s modest gain of 0.5%.For the first quarter of fiscal 2026, MIND incurred a net loss of 12 cents per share compared to breakeven earnings per share in the year-ago quarter. The ...

Inducement Grants Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported a key senior leadership hire to oversee the Company's Chemistry, Manufacturing, and Cont ...

Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities Initiating separate Phase 2a trials to evaluate neflamapimod in patients with primary progressive aphasia and patients in the recovery phase after ischemic stroke BOSTON, May 12, 2025 (GLOBE NEWSWIRE ...